2023
Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis
Goyal A, O’Leary D, Foss F. Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis. Bone Marrow Transplantation 2023, 59: 41-51. PMID: 37853164, DOI: 10.1038/s41409-023-02122-0.Peer-Reviewed Original ResearchConceptsGraft-versus-host diseaseReduced-intensity conditioningDonor lymphocyte infusionAllo-HSCTStem cell transplantationMyeloablative conditioningSezary syndromeOverall survivalMycosis fungoidesCell transplantationRates of graft-versus-host diseaseTreated with donor lymphocyte infusionsChronic graft-versus-host diseaseAllogeneic hematopoietic stem cell transplantationMeta-analysisAdvanced-stage mycosis fungoidesAssociated with superior OSGraft-versus-lymphoma effectOutcomes of allo-HSCTAllogeneic stem cell transplantationHematopoietic stem cell transplantationTreatment of mycosis fungoidesGraft-versus-lymphomaNon-relapse mortalityProgression-free survival
2022
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research
Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation And Cellular Therapy 2022, 28: 187.e1-187.e10. PMID: 35081472, PMCID: PMC8977261, DOI: 10.1016/j.jtct.2022.01.017.Peer-Reviewed Original ResearchMeSH KeywordsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLeukemia, Prolymphocytic, T-CellMiddle AgedTransplantation ConditioningTransplantation, HomologousConceptsDisease-free survivalTreatment-related mortalityKarnofsky performance statusT-cell depletionVivo T-cell depletionAllogeneic hematopoietic cell transplantationInferior disease-free survivalHematopoietic cell transplantationOverall survivalT-cell prolymphocytic leukemiaT-PLLPerformance statusInternational BloodCell transplantationProlymphocytic leukemiaLong-term disease-free survivalMarrow Transplant Research databasePoor long-term survivalOutcomes of alloHCTPart of conditioningPost-transplantation relapseSuboptimal performance statusMyeloablative conditioning regimenReduced-intensity conditioningInferior overall survival
2020
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902
Foss FM, Wang XV, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, Wagner H, Strair RK, Hogan WJ, Sprague KA, Lazarus HM, Litzow MR, Tallman MS, Horning SJ. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion 2020, 60: 1867-1872. PMID: 32654201, PMCID: PMC7606221, DOI: 10.1111/trf.15798.Peer-Reviewed Original ResearchConceptsReduced intensity conditioning regimenIntensity conditioning regimenExtracorporeal photopheresisConditioning regimenChronic extensive GVHDTotal body irradiationChronic graftECOG-ACRINExtensive GVHDGVHD prophylaxisHost diseaseMycophenolate mofetilCell infusionMulticenter trialTolerogenic stateAggressive lymphomaBody irradiationMedian timeMyelodysplastic syndromeGrade 3Day 100PatientsCellular therapyConsecutive daysAdequate engraftment
2017
Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma
Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationT-cell lymphomaAllogeneic hematopoietic stem cell transplantationNovel agentsPeripheral T-cell lymphomaPositive T-cell lymphomaDiagnosis of CD8Retrospective case seriesStandardized treatment strategyStem cell transplantationPotential curative therapyCourse of treatmentPromising treatment modalityHistone deacetylase inhibitorsSustained remissionCombination chemotherapyCurative therapyCase seriesPoor outcomeRare subtypeTreatment courseAvailable therapiesCell transplantationTreatment modalitiesTreatment strategies
2016
Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration
Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.Peer-Reviewed Original ResearchAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugDrug Administration ScheduleEtoposideFemaleHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousMaleMelphalanMiddle AgedTransplantation ConditioningTransplantation, AutologousYoung Adult
2008
Reduced-Intensity and Nonmyeloablative Conditioning Regimens
Foss F, van Besien K. Reduced-Intensity and Nonmyeloablative Conditioning Regimens. Cancer Treatment And Research 2008, 144: 209-232. PMID: 19779868, DOI: 10.1007/978-0-387-78580-6_9.Peer-Reviewed Original Research
2006
The Role of Purine Analogues in Low-Intensity Regimens With Allogeneic Hematopoietic Stem Cell Transplantation
Foss FM. The Role of Purine Analogues in Low-Intensity Regimens With Allogeneic Hematopoietic Stem Cell Transplantation. Seminars In Hematology 2006, 43: s35-s43. PMID: 16549113, DOI: 10.1053/j.seminhematol.2005.12.007.Peer-Reviewed Original ResearchMeSH KeywordsDendritic CellsGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansPurine NucleosidesTransplantation ConditioningTransplantation, HomologousConceptsBone marrow transplantationAllogeneic stem cellsAcute GVHDConditioning regimensExtracorporeal photopheresisDendritic cellsAllogeneic hematopoietic stem cell transplantationLeukemia/lymphoma (GVL) effectT-cell-depleted graftsAllogeneic bone marrow transplantationHematopoietic stem cell transplantationDonor/recipient matchingAlternative stem cell sourceDonor dendritic cellsFull donor engraftmentHost dendritic cellsSevere acute GVHDTransplant-associated morbidityTransplant-associated toxicityMyeloablative conditioning regimensSeverity of GVHDT effector cellsT-cell depletionInduction of immunosuppressionStem cell transplantation
2003
Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease
Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Transplantation And Cellular Therapy 2003, 9: 170-176. DOI: 10.1016/s1083-8791(03)70006-8.Peer-Reviewed Original ResearchConceptsReduced-intensity preparative regimenHost dendritic cellsReduced-intensity regimenPreparative regimenTotal body irradiationDendritic cellsAcute GVHDChronic GVHDDC chimerismConventional regimenBody irradiationAllogeneic bone marrow transplantationAllogeneic bone marrow transplantAllogeneic stem cell transplantationExtensive chronic GVHDDevelopment of GVHDStem cell transplantationBone marrow transplantationBone marrow transplantExtracorporeal photophoresisHost diseaseMarrow transplantationSignificant morbidityMarrow transplantCell transplantation